NASDAQ:SLRX
Salarius Pharmaceuticals Inc. Stock News
$0.536
+0.0373 (+7.47%)
At Close: May 01, 2024
Salarius Pharmaceuticals Inc.'s stock SLRX soared 33% in premarket trade Tuesday after the company said the U.S. Food and Drug Administration has lifted a partial clinical hold on a trial of a treatme
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference
04:02pm, Tuesday, 04'th Apr 2023
HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer
Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models
Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference
08:30am, Wednesday, 19'th Oct 2022
HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer
Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference
12:00pm, Tuesday, 20'th Sep 2022
HOUSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of n
Salarius Pharmaceuticals, Inc.'s (SLRX) CEO David Arthur on Q2 2022 Results - Earnings Call Transcript
02:54pm, Monday, 08'th Aug 2022
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX ) Q2 2022 Earnings Conference Call August 8, 2022 11:00 AM ET Company Participants Kim Golodetz - Senior Vice President, Principal, LHA Investor Relations D
VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to t
Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
04:10pm, Wednesday, 18'th May 2022
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedia
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2022 Results - Earnings Call Transcript
09:32pm, Thursday, 12'th May 2022
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations David Arthur - Chief Executive Of
Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress
07:30am, Thursday, 05'th May 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET
78 Biggest Movers From Yesterday
09:22am, Friday, 11'th Mar 2022 Benzinga
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC ) shares jumped 138.1% to close at $1.50 on Thursday after dropping 37% on Wednesday. AgriFORCE Growing Systems, Ltd. (NASDAQ: AGRI ) gained 102.4% to close at $3.42 after the company announced a binding letter of intent to acquire Deroose Planta NV. Enservco Corporation (NYSE: ENSV ) shares jumped 43.1% to close at $4.32 after dropping 28% on Wednesday. Hoth Therapeutics, Inc. (NASDAQ: HOTH ) gained 38.8% to close at $0.7968 following circulation of an FDA AccessData.gov listing which showed the company''s c-KIT-targeting candidate received orphan-drug designation. AquaBounty Technologies, Inc. (NASDAQ: AQB ) surged 37.8% to close at $1.93 after the company reported FY21 EPS results were higher year over year. Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX ) jumped 33.4% to close at $0.50. Almaden Minerals Ltd. (NYSE: AAU ) gained 32.9% to settle at $0.4480. Ebix, Inc. (NASDAQ: EBIX ) jumped 31.4% to settle at $41.90 on Thursday. The company recently posted upbeat quarterly sales.
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q4 2021 Results - Earnings Call Transcript
11:09pm, Thursday, 10'th Mar 2022
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q4 2021 Results - Earnings Call Transcript
Salarius Pharmaceuticals Q4 2021 Earnings Preview
10:35pm, Wednesday, 09'th Mar 2022 Seeking Alpha
Salarius Pharmaceuticals (NASDAQ:SLRX) is scheduled to announce Q4 earnings results on Thursday, March 10th, after market close.The consensus EPS Estimate is -$0.09 (+10.0% Y/Y) and…
Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress
07:31am, Thursday, 03'rd Mar 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, March 10, 2022, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, March 10, 2022, 5:00 p.m. ET